{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:54:49Z","timestamp":1788490489607,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.neuropharm.2022.109263","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:03:04Z","timestamp":1663905784000},"page":"109263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent \u03bc-opioid receptor agonists"],"prefix":"10.1016","volume":"221","author":[{"given":"Maria Antonietta","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Tocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Mostallino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Pintori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Ucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Poza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Di Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-4706","authenticated-orcid":false,"given":"M. Paola","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4186","key":"10.1016\/j.neuropharm.2022.109263_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/165122a0","article-title":"A new series of analgesics","volume":"165","author":"Adamson","year":"1950","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109263_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/167153b0","article-title":"Dithienylbutylamines as analgesics","volume":"167","author":"Adamson","year":"1951","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109263_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0022-3565(24)37585-8","article-title":"Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor","volume":"286","author":"Alt","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"14","key":"10.1016\/j.neuropharm.2022.109263_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fnins.2020.00149","article-title":"Novel opioids: systematic web crawling within the e-psychonauts' scenario","volume":"18","author":"Arillotta","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109263_bib5","author":"Baumann"},{"key":"10.1016\/j.neuropharm.2022.109263_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2018.09.006","article-title":"Pharmacological research as a key component in mitigating the opioid overdose crisis","author":"Baumann","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109263_bib7","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R3857","article-title":"Pharmacodynamics and pharmacokinetics of the non-fentanyl synthetic opioid, isotonitazene, in male rats","author":"Baumann","year":"2022","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2022.109263_bib8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/dta.2738","article-title":"Report on a novel emerging class of highly potent benzimidazole NPS opioids: chemical and in vitro functional characterization of isotonitazene","volume":"12","author":"Blanckaert","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2022.109263_bib9","unstructured":"https:\/\/bluelight.org\/xf\/search\/1916937\/?q=isotonitazenes&o=relevance."},{"key":"10.1016\/j.neuropharm.2022.109263_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/syn.10277","article-title":"Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene oprm","volume":"51","author":"Bolan","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2022.109263_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0896-6273(00)80082-3","article-title":"A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine","volume":"16","author":"Bonci","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109263_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2022.109263_bib13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/BF01486702","article-title":"\u00dcber neue starkwirkende Analgetika und ihre klinische Erprobung","volume":"36","author":"Bromig","year":"1958","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.neuropharm.2022.109263_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0306-4522(98)00466-7","article-title":"Reciprocal changes in dopamine responsiveness in the nucleus accumbens shell and core and in the dorsal caudate-putamen in rats sensitized to morphine","volume":"90","author":"Cadoni","year":"1999","journal-title":"Neuroscience"},{"issue":"23","key":"10.1016\/j.neuropharm.2022.109263_bib15","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109263_bib16","first-page":"40","article-title":"Strategies of intervention to limit the novel synthetic opioids (NSO) escalation in Europe","volume":"6","author":"De Luca","year":"2019","journal-title":"Research and Advances in Psychiatry"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109263_bib17","first-page":"140","article-title":"Endocannabinoid 2-arachidonoylglycerol self-administration by sprague-dawley rats and stimulation of in vivo dopamine transmission in the nucleus accumbens shell","volume":"17","author":"De Luca","year":"2014","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109263_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.neuropharm.2015.11.017","article-title":"Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE\/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135","volume":"105","author":"De Luca","year":"2016","journal-title":"Neuropharmacology Jun"},{"key":"10.1016\/j.neuropharm.2022.109263_bib19","series-title":"20th Meeting Committee on Drug Addiction and Narcotics, National Academy of Sciences - National Research Council, Washington D.C., 1\u201313","article-title":"Addendum 1. Physical dependence liability studies in the monkey","author":"Deneau","year":"1959"},{"key":"10.1016\/j.neuropharm.2022.109263_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00284","article-title":"Methods used to evaluate pain behaviors in rodents","volume":"10","author":"Deuis","year":"2017","journal-title":"Front. Mol. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2022.109263_bib21","first-page":"227e241","article-title":"Dopamine and drug addiction: the nucleus accumbens shell connection","volume":"47","author":"Di Chiara","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109263_bib22","unstructured":"https:\/\/drugsforum.com\/search\/2828360\/?q=isotonitazene&o=relevance&c[p][vwcomment][displayorder]=0."},{"key":"10.1016\/j.neuropharm.2022.109263_bib23","series-title":"Risk Assessment Report on the New Psychoactive Substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- Ethanamine (Isotonitazene) in Accordance with Article 5c of Regulation (EC) No 1920\/2006 (As Amended), Risk Assessments","year":"2020"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109263_bib29","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acs.jcim.9b00843","article-title":"Exploring ligand stability in protein crystal structures using binding pose metadynamics","volume":"60","author":"Fusani","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2022.109263_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1476-5381.1982.tb09319.x","article-title":"Spectrum of the \u039c\u2010, \u0394\u2010 and \u039a\u2010binding sites in homogenates of rat brain","volume":"77","author":"Gillan","year":"1982","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109263_bib31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1476-5381.1953.tb00739.x","article-title":"Analgesic and other properties of 3: 3-dithienylalkenylamines","volume":"8","author":"Green","year":"1953","journal-title":"Br. J. Pharmacol. Chemother."},{"issue":"6\u20137","key":"10.1016\/j.neuropharm.2022.109263_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","article-title":"Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution","volume":"24","author":"Greenwood","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109263_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02161117","article-title":"\u00dcber Benzimidazolderivate mit starker analgetischer Wirkung","volume":"13","author":"Gross","year":"1957","journal-title":"Experientia"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109263_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.neuropharm.2022.109263_bib35","unstructured":"Hoffmann, K., Hunger, A., and Rossi, A., 1960. Benzimidazoles. U.S. Patent 2935514A.."},{"key":"10.1016\/j.neuropharm.2022.109263_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u03bc-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109263_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/BF02161116","article-title":"Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-derivate","volume":"13","author":"Hunger","year":"1957","journal-title":"Experientia"},{"key":"10.1016\/j.neuropharm.2022.109263_bib38","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hlca.19600430412","article-title":"Benzimidazol\u2010Derivate und verwandte Heterocyclen III. Synthese von 1\u2010Aminoalkyl\u20102\u2010nenzyl\u2010nitro\u2010benzimidazolen","volume":"43","author":"Hunger","year":"1960","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2022.109263_bib39","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/hlca.19600430323","article-title":"Benzimidazol-Derivate und verwandte Heterocyclen. II. Synthese von 1-Aminoalkyl-2-benzyl-benzimidazolen","volume":"43","author":"Hunger","year":"1960","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2022.109263_bib40","doi-asserted-by":"crossref","first-page":"16446","DOI":"10.1073\/pnas.1105418108","article-title":"Neuronal circuits underlying acute morphine action on dopamine neurons","volume":"108","author":"Jalabert","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2022.109263_bib41","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.107.119560","article-title":"Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data","volume":"323","author":"Kalvass","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109263_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1248\/cpb1953.3.394","article-title":"3-Piperidyl-1, 1-di(2'-thienyl)-but-1-ene as a potent antitussive","volume":"3","author":"Kase","year":"1955","journal-title":"Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2022.109263_bib43","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0165-6147(97)01136-X","article-title":"Differences between natural and recombinant G protein-coupled receptor systems with varying receptor\/G protein stoichiometry","volume":"18","author":"Kenakin","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109263_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1248\/cpb.6.159","article-title":"Studies on thiophene derivatives. I. Syntheses of 2-amino-1,1-di(2-thienyl)alkanols","volume":"6","author":"Kimura","year":"1958","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2022.109263_bib45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jat\/bkaa016","article-title":"Isotonitazene quantitation and metabolite discovery in authentic forensic casework","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib46","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/dta.3115","article-title":"Metonitazene in the United States Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry","volume":"13","author":"Krotulski","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2022.109263_bib47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","author":"Lalovic","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109263_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/npp.2010.190","article-title":"Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells","volume":"36","author":"Lecca","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109263_bib49","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/acs.jmedchem.1c01967","article-title":"A vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl-","author":"Lee","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109263_bib50","author":"Logan"},{"key":"10.1016\/j.neuropharm.2022.109263_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u03bc-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109263_bib52","doi-asserted-by":"crossref","first-page":"16120","DOI":"10.1523\/JNEUROSCI.1572-12.2012","article-title":"Morphine withdrawal enhances constitutive mu-opioid receptor activity in the ventral tegmental area","volume":"32","author":"Meye","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109263_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110686","article-title":"Isotonitazene: fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland","volume":"320","author":"Mueller","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2022.109263_bib54","unstructured":"https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdosedata.htm."},{"key":"10.1016\/j.neuropharm.2022.109263_bib55","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.neuropharm.2022.109263_bib56","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1073\/pnas.92.26.12304","article-title":"Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the \"shell\" as compared with the \"core\" of the rat nucleus accumbens","volume":"92","author":"Pontieri","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2022.109263_bib57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neuropharm.2018.01.024","article-title":"Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G\u03b1i\/o protein inhibitor","volume":"133","author":"Porcu","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109263_bib58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J. Addiction Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109263_bib59","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acs.jcim.0c00890","article-title":"Structural assessment of agonist efficacy in the \u03bc-opioid receptor: morphine and fentanyl elicit different activation patterns","volume":"61","author":"Ricarte","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2022.109263_bib60","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hlca.19600430413","article-title":"Benzimidazol\u2010Derivate und verwandte Heterocyclen. IV. Die Kondensation von o\u2010Phenylendiamin mit \u03b1\u2010Aryl\u2010 und \u03b3\u2010Aryl\u2010acetessigester","volume":"43","author":"Rossi","year":"1960","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2022.109263_bib61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02249408","article-title":"Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure","volume":"125","author":"Salamone","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109263_bib62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.neuropharm.2022.109263_bib70","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/mol.51.1.87","article-title":"mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy","volume":"51","author":"Selley","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib71","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","article-title":"Signal transduction correlates of Mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP\u03b3S binding in mMOR-CHO cells and rat thalamus","volume":"285","author":"Selley","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109263_bib72","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/ejp.1728","article-title":"Is Europe facing an opioid epidemic: what does European monitoring data tell us?","volume":"25","author":"Seyler","year":"2021","journal-title":"Eur. J. Pain"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109263_bib73","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109263_bib74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ADM.0000000000000775","article-title":"Emerging characteristics of isotonitazene-involved overdose deaths: a case-control study","volume":"15","author":"Shover","year":"2021","journal-title":"J. Addiction Med."},{"key":"10.1016\/j.neuropharm.2022.109263_bib75","series-title":"Technical Review of New Synthetic Opioids Identified on the European Drug Market. Part 1. Benzimidazole Opioids","author":"Ujv\u00e1ry","year":"2020"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109263_bib76","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","article-title":"DARK classics in chemical neuroscience: etonitazene and related benzimidazoles","volume":"12","author":"Ujv\u00e1ry","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109263_bib77","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the Drug Enforcement Administration by the Veterans Affairs","article-title":"Isotonitiazene.N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H- benzimidazole-1-ethanamine. Binding and functional activity at delta, kappa and mu opioid receptors","year":"2019"},{"key":"10.1016\/j.neuropharm.2022.109263_bib79","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1007\/s00204-020-02855-7","article-title":"In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances","volume":"94","author":"Vandeputte","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib80","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109263_bib81","article-title":"The rise and fall of isotonitazene and brorphine: two recent stars in the synthetic opioid firmament","author":"Vandeputte","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib82","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00204-022-03294-2","article-title":"First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib83","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","article-title":"Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pharmtox-010611-134625","article-title":"Addiction circuitry in the human brain","volume":"52","author":"Volkow","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109263_bib86","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.csbj.2022.05.013","article-title":"A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the \u03bc-opioid receptor","volume":"20","author":"Xie","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.neuropharm.2022.109263_bib87","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0028-3908(88)90141-4","article-title":"Comparative binding of \u03bc and \u03b4 selective ligands in whole brain and pons\/medulla homogenates from rat: affinity profiles of fentanyl derivatives","volume":"27","author":"Yeadon","year":"1988","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109263_bib88","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1021\/ci4002475","article-title":"MMGBSA as a tool to understand the binding affinities of filamin-peptide interactions","volume":"53","author":"Ylilauri","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2022.109263_bib89","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0306-4522(99)00046-9","article-title":"Fentanyl increases dopamine release in rat nucleus accumbens: involvement of mesolimbic MU- and delta-2-opioid receptors","volume":"92","author":"Yoshida","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109263_bib90","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2017.08.034","article-title":"14-O-Methylmorphine: a novel selective mu-opioid receptor agonist with high efficacy and affinity","volume":"814","author":"Z\u00e1dor","year":"2017","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:02Z","timestamp":1758439142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":76,"alternative-id":["S0028390822003227"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109263","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent \u03bc-opioid receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109263"}}